Tag: Drug discovery
Model Medicines, Sanford Burnham Prebys forge AI-driven drug discovery partnership
AI drug discovery software company Model Medicines has signed a multi-target collaboration agreement with California-based Sanford Burnham Prebys Medical Discovery Institute for identifying and developing ... Read More
Roivant Sciences to acquire Silicon Therapeutics to boost drug discovery capabilities
Roivant Sciences has agreed to acquire Silicon Therapeutics, a Boston-based drug design, research, and development company, for $450 million, in an all-share deal. The Swiss ... Read More
PostEra, Pfizer partner to advance machine learning for drug discovery
PostEra, a biotech company specializing in machine learning solutions for preclinical drug discovery, has forged a partnership with Pfizer for speeding up the discovery of ... Read More
PharmaEngine, Sentinel Oncology partner to advance SOL-578 Chk1 inhibitor
PharmaEngine has signed a collaboration and license deal with UK-based Sentinel Oncology for advancing the new drug development of SOL-578, a checkpoint kinase 1 inhibitor ... Read More
PerkinElmer to acquire cell engineering company Horizon Discovery
US-based PerkinElmer will acquire UK-based cell engineering company Horizon Discovery Group for nearly $383 million in an all-cash deal. The transaction, which is subject to ... Read More
Ligand Pharmaceuticals to acquire protein therapeutics developer Pfenex
US biopharma company Ligand Pharmaceuticals has signed a deal worth up to $516 million to acquire Pfenex, a development and licensing biotechnology company engaged in ... Read More
Curi Bio acquires Dana Solutions to boost drug discovery platforms
Curi Bio, a developer of human iPSC-based platforms for drug discovery, has acquired Dana Solutions, a provider of artificial intelligence and machine learning technologies for ... Read More
Cyclica, Genome Institute of Singapore sign drug discovery partnership
Canadian biotech company Cyclica has signed a multi-year and multi-project drug discovery partnership with the Genome Institute of Singapore (GIS) in oncology and related diseases. ... Read More
Gilead Sciences, Second Genome form IBD drug discovery alliance
Gilead Sciences has entered into a four-year deal worth up to $338 million with California-based clinical-stage company Second Genome to discover targets and drug candidates ... Read More
Polarisqb, Fujitsu join forces to create dengue drug discovery platform
Polarisqb has joined forces with Fujitsu to create a Dengue drug discovery platform that brings together quantum-inspired technology, hybrid quantum mechanics, machine learning, and molecular ... Read More